Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Aclaris Therapeutics Inc

Healthcare US ACRS

4.465USD
-0.245(5.20%)

Last update at 2026-06-05T15:34:00Z

Day Range

4.464.70
LowHigh

52 Week Range

1.164.89
LowHigh

Fundamentals

  • Previous Close 4.71
  • Market Cap504.93M
  • Volume172312
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-74.03500M
  • Revenue TTM7.83M
  • Revenue Per Share TTM0.06
  • Gross Profit TTM -52.10300M
  • Diluted EPS TTM-0.53

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -64.92300M -132.06500M -88.84800M -86.90800M -90.86500M
Minority interest - - - - -
Net income -64.92300M -132.06500M -88.48100M -88.66200M -114.28100M
Selling general administrative 21.97M 22.20M 31.10M 25.13M 23.62M
Selling and marketing expenses - - - - -
Gross profit 5.74M 15.93M 13.17M 17.79M 2.05M
Reconciled depreciation 0.45M 0.81M 0.86M 0.80M 0.92M
Ebit -64.92300M -52.52700M -116.31400M -85.15400M -65.38400M
Ebitda -64.46900M -51.72000M -115.45100M -79.65700M -41.04500M
Depreciation and amortization 0.45M 0.81M 0.86M 5.50M 24.34M
Non operating income net other - - - 2.95M -1.14200M
Operating income -76.37500M -141.93200M -97.35700M -85.15400M -65.38400M
Other operating expenses 84.20M 160.65M 128.61M 114.91M 72.14M
Interest expense - - - 4.70M 23.42M
Tax provision - 0.00000M -0.36700M 0.00000M 0.00000M
Interest income 7.64M 7.95M - - -
Net interest income 7.64M 7.95M - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - -0.36700M 1.75M 23.42M
Total revenue 7.83M 18.72M 31.25M 29.75M 6.76M
Total operating expenses 82.11M 157.86M 110.53M 102.95M 67.43M
Cost of revenue 2.09M 2.79M 18.08M 11.96M 4.71M
Total other income expense net 11.45M 9.87M 8.51M -1.75400M -25.48100M
Discontinued operations - - - - -
Net income from continuing ops -64.92300M -132.06500M -88.48100M -86.90800M -90.86500M
Net income applicable to common shares - - - -86.90800M -90.86500M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 160.46M 220.33M 197.41M 254.60M 251.21M
Intangible assets - - 0.27M 6.97M 7.05M
Earning assets - - - - -
Other current assets 55.05M 12.04M 9.45M 13.49M 12.99M
Total liab 57.38M 64.77M 40.23M 56.98M 53.87M
Total stockholder equity 103.08M 155.55M 157.18M 197.62M 197.34M
Deferred long term liab - - - 0.37M 0.37M
Other current liab 14.94M 23.02M 2.20M 10.90M 2.20M
Common stock 0.00100M 0.00100M 0.00100M 0.00100M 0.00100M
Capital stock 0.00100M 0.00100M 0.00100M 0.00100M 0.00100M
Retained earnings -967.78400M -902.86100M -770.79600M -682.31500M -595.40700M
Other liab - - - 33.47M 28.77M
Good will - - - - -
Other assets - - - 1.74M 251.21M
Cash 19.96M 24.57M 39.88M 45.28M 27.35M
Cash and equivalents - - - - -
Total current liabilities 28.64M 31.60M 30.95M 21.94M 22.93M
Current deferred revenue - 3.89M 19.45M - 10.05M
Net debt -17.84400M -24.57000M -39.45200M -44.59300M -26.65600M
Short term debt 0.55M 0.96M 0.43M 0.68M 0.69M
Short long term debt - - - - -
Short long term debt total 2.12M 2.60M 0.43M 0.68M 0.69M
Other stockholder equity 1070.26M 1058.32M 928.08M 880.83M 792.97M
Property plant equipment - - - 1.10M 1.33M
Total current assets 151.36M 125.95M 128.86M 231.55M 205.03M
Long term investments 60.61M 90.30M 62.77M 12.24M 34.24M
Net tangible assets - - - 190.65M 190.29M
Short term investments 70.79M 89.02M 79.23M 172.29M 164.06M
Net receivables 5.57M 0.32M 0.30M 0.48M 0.62M
Long term debt - - - - -
Inventory - - - -12.24200M -34.24200M
Accounts payable 13.16M 4.69M 8.88M 10.35M 9.98M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.61M 0.10M -0.10600M -0.89700M -0.22400M
Additional paid in capital - - - - -
Common stock total equity - - - 0.00100M 0.00100M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -682.31500M -595.40700M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -51.51500M 3.07M 1.74M 2.73M 3.55M
Deferred long term asset charges - - - - -
Non current assets total 9.10M 94.38M 68.55M 23.05M 46.18M
Capital lease obligations - - 0.43M 0.68M 0.69M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 49.31M -69.76900M 46.22M 12.63M -167.32400M
Change to liabilities - - - 0.96M 4.12M
Total cashflows from investing activities 48.37M -69.76900M 46.22M 12.63M -167.63200M
Net borrowings - - 0.00000M - -11.48300M
Total cash from financing activities -5.86200M 74.54M 26.71M 72.87M 225.05M
Change to operating activities - - - -1.70200M -5.14700M
Net income -64.92300M -132.06500M -88.48100M -86.90800M -90.86500M
Change in cash -4.61000M -15.30800M -5.39900M 17.93M 5.29M
Begin period cash flow 24.57M 39.88M 45.28M 27.35M 22.06M
End period cash flow 19.96M 24.57M 39.88M 45.28M 27.35M
Total cash from operating activities -47.11300M -20.07500M -78.32500M -67.56700M -52.13400M
Issuance of capital stock 0.00000M 74.91M 26.71M 72.74M 238.20M
Depreciation 0.45M 0.81M 0.86M 0.80M 0.92M
Other cashflows from investing activities -0.83300M -35.81000M - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 6.14M -0.02000M 0.19M 0.14M 0.15M
Sale purchase of stock - - -0.10200M 72.90M 239.66M
Other cashflows from financing activities -5.86200M -0.37700M -0.00800M 0.12M -1.66500M
Change to netincome - - - 19.74M 39.15M
Capital expenditures 0.11M 0.12M 1.31M 0.60M 0.31M
Change receivables - - - 0.14M 0.15M
Cash flows other operating - - - -2.29400M -5.61700M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - 17.93M 5.29M
Change in working capital 2.67M 10.92M 9.39M -1.19500M -1.34300M
Stock based compensation 12.38M 10.86M 20.54M 15.04M 14.06M
Other non cash items 2.30M 89.41M -20.27100M 4.70M 24.34M
Free cash flow -47.11300M -20.19600M -79.63400M -68.17200M -52.44200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ACRS
Aclaris Therapeutics Inc		 -0.245 5.20% 4.46 - - 64.52 4.91 53.08 0.28
NVO
Novo Nordisk A/S		 -0.015 0.03% 43.73 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.0037 0.0084% 44.19 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 7.17 1.62% 448.90 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 7.53 1.20% 636.26 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Aclaris Therapeutics Inc

701 Lee Road, Wayne, PA, United States, 19087

Key Executives

Name Title Year Born
Dr. Neal S. Walker D.O. Co-Founder, CEO & Director 1970
Mr. Frank Ruffo Co-Founder, CFO & Treasurer 1966
Dr. Joseph Monahan Chief Scientific Officer NA
Dr. Douglas J. Manion Frcp(C), M.D. Pres & COO 1961
Mr. Robert A. Doody Jr. VP of Investor Relations NA
Mr. Matthew Rothman J.D. Gen. Counsel & Corp. Sec. NA
Dr. Jon Jacobsen Ph.D. Sr. VP of Chemistry NA
Dr. Paul S. Changelian Ph.D. Sr. VP of Biology NA
Mr. James Loerop Chief Bus. Officer 1965
Dr. Ian Anderson Ph.D. Exec. VP of Translational R&D NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.